Despite being an essential vitamin, folate has been implicated to enhance tumor growth, as evidenced by reports on overexpression of folate receptor alpha (FRa) in carcinomas. The role of another folate transporter, reduced folate carrier (RFC), is largely unknown. This study investigated the roles of folate, FRa and RFC in ovarian cancers. We demonstrated FRa mRNA and protein overexpression and reduced RFC expression in association with FRa gene amplification and RFC promoter hypermethylation, respectively. FRa overexpression was associated with tumor progression while RFC expression incurred a favorable clinical outcome. Such reciprocal expression pattern was also observed in ovarian cancer cell lines. Folate was shown to promote cancer cell proliferation, migration and invasion in vitro, and down-regulate E-cadherin expression. This effect was blocked after either stable knockdown of FRa or ectopic overexpression of RFC. This hitherto unreported phenomenon suggests that, RFC can serve as a balancing partner of FRa and confer a protective effect in patients with high FRa-expressing ovarian carcinomas, as evidenced by their prolonged overall and disease-free survivals. In conclusion, we report on the paradoxical impact of FRa (putative oncogenic) and RFC (putative tumor suppressive) in human malignancies. FRa and RFC may potentially be explored as therapeutic target or prognostic marker respectively. We recommend caution and additional research on folate supplements in cancer patients.
Introduction
Ovarian carcinomas account for the highest mortality amongst all gynecological cancers in the world [1, 2] . While the incidence of ovarian carcinomas varies between different ethnic groups, its incidence in Asian countries is on a rising trend [3, 4] . The reasons for this remain largely unknown or controversial. Several lifestyle risk factors have been implicated. These include diet, obesity, fertility and parity statuses. On the other hand, it has became a general belief that high intake of micronutrients such as folate, vitamin C, vitamin E may protect against cancers [5] . As such, better understanding of the effects of nutritional elements on carcinogenesis is important to improve the strategies for cancer prevention and management.
Folate is a water-soluble B vitamin found in most vegetables. A high dietary folate intake has been reported to associate with a lower risk of developing ovarian cancers, in particular, those who consume alcohol [6, 7, 8, 9] . It is closely related to its function on DNA synthesis and its involvement in the related methionine metabolic pathway essential for DNA methylation. Folate deficiency would therefore leads to DNA hypomethylation, altered gene expression and the misincorporation of uracil into DNA, leading to chromosome damage, all of which, are key factors for carcinogenesis [10, 11] . It would appear that folate is an important vitamin essential in normal functioning of cells, and to prevent the initiation of cancer. However, there is increasing evidence to show that folate may in fact enhance cancer progression in established carcinomas of colon and rectum, breast and prostate [12, 13, 14] .
Folate uptake involves several transporters, such as folate receptors, and reduced folate carrier (RFC) [15, 16] . Folate receptor alpha (FRa), a single chain glycosyl-phosphatidylinositol-anchored membrane protein, enhances folate uptake through endocytosis. Its overexpression has been reported in ovarian cancers, implying that it may promote tumor growth [17, 18, 19, 20] . RFC is an ubiquitously expressed transporter for natural folates and classical antifolates, and can control folate uptake in a bi-directional manner [16] . Loss of RFC with subsequent effects of folate deficiency was found to promote cancer progression in colorectal cancer [16, 21] . It would therefore be logical to assume that these two folate transporters, FRa and RFC, exert different effects in cancer progression.
Although overexpression of FRa in ovarian cancers has been established, the expression status and functional roles of RFC remain largely unknown. In this study, we investigated the expression, genetic and epigenetic profiles of FRa and RFC in normal ovarian epithelium and ovarian cancer, and correlated with clinicopathological parameters. Their functional roles and possible downstream targets on cell proliferation, migration and invasion in relation to folate in ovarian cancer were also assessed. We endeavoured to better understand the roles of folate and its transporters in ovarian carcinogenesis, and explore the possible effects of folate intake in cancer patients.
Materials and Methods

Clinical Samples and cell lines
One hundred and fifty three formalin-fixed paraffin embedded samples of ovarian tumors, including 11 inclusion cysts/benign cystadenomas (22- (Table 1) , were collected from the Department of Pathology, Queen Mary Hospital, the University of Hong Kong. All patients underwent surgery and 67 patients with ovarian cancers were also treated with chemotherapy including platinum/paclitaxel. The follow-up period ranged from five to 209 months (mean 63 months). Thirty three randomly selected clinical samples of ovarian tumors and their corresponding normal counterparts, including fallopian tubes and/or contralateral ovaries, with available frozen blocks were also retrieved. Informed consent was obtained by all patients and the use of these clinical samples was approved by Institutional Review Board of the University of Hong Kong/Hospital Authority Hong Kong West Cluster (HKU/HA HKW IRB)(Institutional Review Board number: UW10-129). Haematoxylin Eosin stained sections of the frozen blocks of each sample were reviewed by two of us (A.N.Y.C. and P.P.C.I.) to confirm the diagnosis and to ensure that more than 80% tumor cells were present in the tumor blocks.
Two immortalized ovarian epithelial cell lines, HOSE 6-3 and HOSE 17-1, and nine ovarian cancer cell lines, SKOV-3, OVCAR-3, OVCA 420, OVCA433, OC316, Dov13, ES-2, TOV21G, SW626 (ATCC; Manassas, VA) were cultured as previously described [22, 23] .
Real-time PCR (qPCR)
Total RNA from frozen clinical samples and cancer cell lines was extracted using Trizol reagent (Invitrogen). Genomic DNA contamination was removed by treating with DNase I (Invitrogen) treatment. 2.5 mg total RNA was reverse transcribed by SuperScript Reverse Transcriptase (Invitrogen, San Diego, CA). Genomic DNA was extracted using phenol/chloroform (Invitrogen). qPCR was performed with ABI Prism 7700 sequence detection system (Applied Biosystems, Foster City, CA) as described [22, 23, 24] . Primer sequences for evaluating mRNA expression of FRa, RFC and GAPDH (as internal control) were as follows: FRa sense, 59-AAGTGCGCAGTGGGAGCT -39, and antisense, 59-CATTGCACAGAACAGTGGGTG -39; RFC sense, 59-CGAAACCTCGGCTTCGGAGC -39, and antisense, 59-GCACGTAGTAGACCACCAGG -39; GAPDH sense, 59-TCCATGACAACTTTGGTATCGTG -39, and antisense, 59-ACAGTCTTCTGGGTGGCAGTG -39. The PCR purity was confirmed by gel electrophoresis. Primer sequences (sense, 59-GTATGCATGGCTTCCTGCAGG -39, and antisense, 59-ACTTGTTAAACCCTGTAGAGAGG -39) for evaluating FRa gene copy number were designed based on the genomic sequence of intron 3 and intron 4 of FRa (Ensemble database). TRAT1 was used as the reference gene [25] . Ovarian cancer samples having $ two-fold increase from their corresponding normal counterparts were considered as positive for FRa gene amplification.
Immunoblotting
Cells were harvested with lysis buffer (0.125 M Tris, pH 6.8 at 22uC containing 1% NP-40 (v/v), 2 mM EDTA, 2 mM Nethylmaleimide, 2 mM PMSF, 1 mM sodium orthovanadate and 0.1 mM sodium okadate], and cleared by centrifugation at 4uC. Protein concentration was determined by DC (detergent compatible) protein assay (Bio-Rad Laboratories, Hercules, CA). 20 mg protein was resolved by SDS-PAGE, transferred to polyvinylidene difluoride membrane, and hybridized with antibodies specific to FRa (1:1000; Alexis Biochemical, San Diego, CA; ALX-804-439), RFC (1:1000; Affinity BioReagents; Golden, CO; PA1-9553), E-cadherin (1:5000; BD Biosciences; Palo Alto, CA; 610182), and actin (1:1000; Sigma, St. Louis, MO; A5060) and appropriate secondary antibodies (Santa Cruz Biotechnology, Santa Cruz, CA). The blots were developed by Enhanced Chemiluminescence (ECL) Plus detection system (Amersham, Arlington Heights, UK), and visualized with X-ray film (Galen Medical Group, Chattanooga, TN) [22, 23, 24] .
Immunohistochemistry
Immunohistochemical staining was performed as described in earlier reports [22, 23, 24] . For FRa immunohistochemistry, paraffin sections were treated with goat anti-folate receptor antibody conjugated with horse radish peroxidase (1:200; Abcam; Cambridge, MA; ab20572). Since the anti-FRa antibody from Alexis Biochemical used for immunoblotting failed to have satisfactory result on immunostaining using paraffin sections, another antibody from Abcam was used. Although this antibody may recognize other isoforms of FR, the beta and gamme isoforms of FR were reported to be predominantly expressed in placenta and hematopoetic cells but not in other tissues [26, 27] . This antibody can therefore be used to detect FRa immunoreactivity in ovarian cancers. For RFC immunohistochemistry, chicken anti-RFC antibody (1:200; Affinity BioReagents) was applied, followed by biotin-rabbit anti-chicken IgG (H+L). 3-diaminobenzidinehydrogen peroxide was used as chromogen. Microwave antigen recovery using citrate buffer (pH 6.0) was performed. Omission or substitution of the primary antibody with preimmune IgG serum was used as a negative control. Intensity in stained epithelial cells was scored as 0 (negative), 1 (faint), 2 (moderate), and 3 (strong). The percentage of stained cells was rated as 0 (,5%), 1 (5%-25%), 2 (26%-50%), 3 (51%-75%) and 4 (.75%). Immunoreactivity was assessed by multiplying the staining intensity by the percentage of stained cells to give a composite a composite ''Histoscore'' [22, 23] . High and low levels of FRa and RFC were defined by ''HistoScores'' cut off at mean.
Demethylation treatment
SKOV-3 and OVCA420 cells were treated with 0, 5 or 10 mM 5-Aza-29-deoxycytidine (5-aza-dc, a DNA methylation inhibitor) for 72 hours [28] . Control cells were treated with equal volume of dimethyl sulfoxide (DMSO). Total RNA was extracted from cells. The transcription activity of RFC was determined by qPCR.
DNA preparation, bisulfite treatment and methylationspecific PCR (MSP) analysis
Genomic DNA from frozen clinical samples was extracted using phenol/chloroform. Bisulfite treatment was performed as described [28] . Primers specific to the methylated (sense, 59-TTCGTCGTAGTTTGCGAATG -39, and antisense, 59-CAA-CACGTACCTAAACGCGA -39) and unmethylated (sense, 59-TTTGTTGTAGTTTGTGAATGG -39, and antisense, 59-ACAACACATACCTAAACACAA -39) RFC promoter A were reported previously [29] . The annealing temperature was 52uC and 56uC for methylated and unmethylated promoter A respectively. MSP products were detected by electrophoresis on 2% agarose gel with ethidium bromide staining. Normal lymphocyte DNA methylated with Sssl methyltransferase was used as positive control. Untreated genomic DNA and water blanks without DNA were used as negative controls.
Stable knockdown of FRa, ectopic overexpression of RFC and folate treatment in SKOV-3 SKOV-3, an ovarian cancer cell line with relatively high FRa and low RFC expression, was used. To stable knockdown FRa, cells were transfected with a set of shRNA constructs against human FRa, pRS-sh FRa (Origene, Rockville, MD), selected with puromycin (1.5 mg/ml) [22, 23, 24] . The pRS vector was used as controls. To transient overexpress RFC, pcDNA3-RFC plasmid (kindly provided by Prof L Matherly, Michigan Cancer Foundation) and the empty pcDNA3 vector (control) was transfected into control SKOV-3 cells using Lipofectamine 2000 (Invitrogen) [22, 23, 24] . Cells were cultured in Medium 199 (Invitrogen)/ MCDB 105 (Sigma) medium containing 22.7 nM folic acid and supplemented with 10% fetal bovine serum (FBS) (JRH Biosciences, Lenexa, KS) [22, 23] . shFRa cells and RFC overexpressing cells (2 days after transfection) were pretreated with folate-free RPMI 1640 medium (Invitrogen) supplemented with 10% dialyzed FBS containing 0.6 nM folic acid (Invitrogen) for 2 days, trysinized, counted, plated for functional assays and then treated with different doses of folic acid, a synthetic folate, including 0, 6, 12 and 60 nM. The folic acid concentrations used are based on the physiological range in plasma, which ranges from ,7 nM in individuals with a negative folate balance to .50 nM in individuals with .400 mg/d of folate consumption [30] , which is the estimated folate intake by supplement nonusers in North America [13] . The folic acid deficiency concentration selected (12 nM) was based on the observation that such concentration is the lowest requirement for cell growth [31] . Protein was extracted 2 days after treatment.
MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide) assay
Cell proliferation was determined by MTT assay (Sigma) as described [22, 24] . Cells were seeded in 96-well plates with 2000 cells/well. At specific time points, 10 ml MTT was added to each well. Plates were incubated at 37uC for 4 h, followed by addition of 100 ml DMSO to each well for dye extraction. Cell proliferation was determined by measuring the absorbance of samples at 570 nm with 630 nm as the reference wavelength.
In vitro migration and invasion assays
In vitro migration and invasion assays were performed as described [22, 23, 24] 
Statistical Analysis
Statistical analysis was performed using SPSS 15.0 for Windows (SPSS Inc., Chicago, IL). Mann-Whitney test was used for comparison between two groups whereas Kruskal-Wallis rank test was used for comparison among multiple groups. Survival analysis was performed by Kaplan-Meier analysis and log-rank test. Cox regression analysis was used for multivariate survival analysis. P values,0.05 were considered as statistically significant.
Results
Overexpression of FRa was associated with ovarian tumor progression
By qPCR, significantly higher FRa mRNA was found in cancer samples when compared with the corresponding non-tumor counterparts after normalization with GAPDH (P = 0.015) ( Figure 1A) . By immunohistochemistry, strong FRa immunoreactivity was observed in ovarian cancers in contrast to moderate staining of FRa in borderline tumors and weak or absence of staining in benign cystadenomas/inclusion cysts ( Figure 1C ). Indeed, significantly higher FRa immunoreactivity was detected in ovarian cancers and borderline tumors than in benign cystadenomas/inclusion cysts (all P,0.05, TOV21G showed weak expression when compared with two normal ovarian epithelium cell lines in which no FRa mRNA and protein expression was detected ( Figure 1B) . In clinical samples, high FRa mRNA expression and immunoreactivity were found to be significantly associated with advanced stages of disease and poor histological grade, factors associated with tumor aggressiveness (Tables 1 and 2 ). However, no significant difference of FRa immunoreactivity was found between the chemosensitive and chemoresistant cases (Table 1) . KaplanMeier-survival analyses also did not reveal association between high FRa expression and overall or disease-free survival ( Figure 1D ).
RFC was down-regulated in ovarian cancers and correlated with good prognosis of patients
In contrast to FRa, ovarian cancer samples displayed significantly lower RFC mRNA when compared with the corresponding non-tumor counterparts as assessed by qPCR (P = 0.001) (Figure 2A ). Immunohistochemical analysis also revealed strong RFC immunoreactivity in inclusion cysts/benign cystadenomas and weak expression in ovarian cancers ( Figure 2C ). Six out of nine ovarian cancer cell lines also displayed down-regulation of RFC mRNA and protein expression when compared with two normal ovarian epithelium cell lines ( Figure 2B ).
RFC mRNA and immunoreactivity did not correlate with stages of disease, histological grade and histological subtypes (Tables 1 and 2 ). Interestingly, there was a significant association between low expression of RFC, and shorter overall (P = 0.034) and disease-free (P = 0.011) survival ( Figure 2D ). Moreover, among ovarian cancers with high FRa expression, the overall (P = 0.007) and disease-free (P = 0.008) survival was significantly longer in those with high RFC expression ( Figure 2E ).
FRa gene amplification and RFC promoter methylation contributed to dysregulated gene expression in ovarian cancers
By qPCR, 11 out of 33 (33.3%) cancer samples displayed FRa gene (FOLR1, chromosome 11q13.3) amplification when compared with the corresponding non-tumor counterparts. All amplified cases showed elevated mRNA expression. FRa amplification was correlated with its mRNA expression (P,0.001, Fisher's exact test) ( Table 3) .
On the other hand, reduced expression of RFC in ovarian cancers was related to hypermethylation. After treatment of SKOV-3 and OVCA420 ovarian cancer cells by 5-aza-dc, a DNA methylation inhibitor, two-fold and 2.5-fold increase of RFC gene expression was detected respectively ( Figure 3A) . Furthermore, promoter hypermethylation of RFC gene (chromosome 21q22.2) was found in 14 out of 33 (42.4%) ovarian cancer samples by MSP. Representative examples of MSP were shown in Figure 3B . In contrast, only 3 out of 33 (9%) of non-tumor samples showed hypermethylation. Unmethylated alleles were detected in all tumor and non-tumor samples. Promoter hypermethylation of RFC significantly inversely correlated with its mRNA expression (P = 0.005, Fisher's exact test) ( Table 3) . By MSP, we also detected RFC promoter hypermethylation in five ovarian cancer cell lines SKOV-3, OVCA 420, OVCA433, TOV21G and SW626 ( Figure 3B ), all of them showed down-regulated RFC mRNA and protein expression ( Figure 2B ). In contrast, no methylated alleles were detected ( Figure 3B ) in the normal ovarian epithelium cell line HOSE 6-3 and two cancer cell lines OVCAR-3 and OC316, which displayed RFC mRNA and protein expression ( Figure 2B ), 
Folate through FRa induced SKOV-3 cell migration and invasion and down-regulated E-cadherin
Next, we tested the effect of folate and FRa on SKOV-3 cell migration and invasion. Based on the effects of folate on cell proliferation, 12 and 60 nM doses were chosen for treating control and shFRa SKOV-3 cells. Transwell migration and invasion assays showed that 12 and 60 nM folate significantly induced cell migration and invasion in control cells whereas knockdown of FRa blocked folate-mediated cell migration and invasion ( Figure 4C ). We then determined the possible downstream target for folate mediated effect on cell migration and invasion. The expression of E-cadherin, an important cell-cell adhesion molecule essential for regulating cell motility, was found to be reduced does-dependently after folate treatment ( Figure 4D ). Such down-regulation of E- cadherin after folate treatment was also abrogated after knockdown of FRa.
Ectopic overexpression of RFC in high FRa-expressing SKOV-3 counteracted folate-mediated cell proliferation, migration and invasion and restored E-cadherin expression
We have demonstrated overexpression of FRa and reduced expression of RFC in ovarian cancers, suggesting that they may exert opposite roles in the progression of ovarian cancer. More importantly, in patients with high FRa, the overall and diseasefree survival was significantly longer in those with high RFC expression, implicating the protective role of RFC in high FRa cancers. To elucidate such protective role, in vitro functional studies were performed on FRa-positive SKOV-3 cells with ectopically expressed RFC after folate treatment. RFC was found to counteract folate-mediated cell proliferation ( Figure 5A ), migration and invasion ( Figure 5B ). Moreover, down-regulation of Econtrol without folate treatment (0 nM). n = 3; *, P,0.05. cadherin in cells after folate treatment was also abrogated after overexpressing RFC ( Figure 5C ).
Discussion
In this study, we demonstrated the progressive increase in FRa mRNA and protein expression from non-tumor tissues, benign and borderline tumors to carcinomas. In addition, FRa gene amplification as a possible mechanism of its overexpression was also demonstrated for the first time in ovarian cancers. Overexpression of FRa in ovarian cancers [19, 20] as well as in cancers of kidney, lung and breast have been previously reported [32] . Our results also indicate that a high FRa expression correlates with poor histological grade and advanced stages of disease, suggesting its roles in ovarian tumor progression.
In contrast to FRa, a lower RFC mRNA and protein expression in ovarian cancers was found when comparing with normal tissues or benign tumors. RFC is ubiquitously expressed in normal tissue and is the major folate transport system for transporting natural folates, such as 5-methyl or 5-formyl tetrahydrofolate (THF), and antifolates such as methotrexate (MTX) and pemetrexed [16] . 5-methyl THF is a cofactor essential for DNA methylation which normally leads to the suppression of oncogenes [33] . Thus, loss of RFC has been described to contribute to colonic carcinogenesis [21] . In this study, we found that reduced expression of RFC was significantly associated with shorter overall and disease-free survivals, suggesting that RFC may be considered as a marker for good prognosis in ovarian cancer patients. Moreover, among patients with high FRa expressing ovarian cancers, the overall and disease-free survival was significantly better in those with high RFC expression than those without, implicating the protective role of RFC for patients with these tumors.
We also demonstrated that FRa amplification and RFC promoter methylation correlated with mRNA expression in ovarian cancers. In earlier reports, RFC promoter methylation has been found in breast cancer cells [34] and primary lymphomas [35] . Our findings suggested that up-regulation of FRa (a putative oncogenic folate transporter) and down-regulation of RFC (a putative tumor suppressor type folate transporter) were controlled genetically and epigenetically respectively during ovarian cancer development.
As noted in the introduction above, folate is essential for DNA synthesis [12, 13, 14] , thereby indirectly exerts its effect on cell proliferation. Overexpression of the FRa in NIH/3T3 cells has been reported to induce increased cell growth in vitro and in vivo [36] . Using folate at various dosages ranging from 12 nM (considered as dietary deficient in North America) to 60 nM (considered normal for supplement non-users), we were able to demonstrate cell proliferation in FRa-positive SKOV-3 cells [13] . Conversely, when the FRa was knockdown by shRNA approach, this folate-mediated cell proliferation in SKOV-3 cells was lost, confirming the fact that folate indeed transports through FRa during the process of ovarian cancer cell proliferation. Similarly, intracellular expression of anti-FR antibodies in ovarian cancer cells has been reported to exert growth inhibitory effects as shown by reduced colony formation in soft agar [37] .
Besides its effects on cell proliferation, we also demonstrated for the first time that folate increased SKOV-3 cell migration and invasion, possibly through the downregulation of cell-cell adhesion molecule E-cadherin. This effect was abrogated after the knockdown of FRa. In ovarian cancer, reduced E-cadherin expression has been described in the metastases but not in the corresponding primary ovarian tumors [38] . Patients with such loss of E-cadherin expression were found to have significantly shorter survival [39] . Moreover, simultaneous expression of caveolin-1 and E-cadherin in ovarian cancer cells stabilized adherens junctions through inhibition of src-related kinases [40] whereas loss of E-cadherin enhanced ovarian cancer metastasis through up-regulation of a5-integrin [41] . In our study, we were able to show E-cadherin down-regulation in folated-treated SKOV-3 cells, suggesting that the folate-mediated enhancing effect on ovarian cancer cell migration and invasion probably acts through FRa via down-regulation of E-cadherin expression.
Interestingly, our study also demonstrates folate-mediated cell proliferation, migration, invasion and E-cadherin reduction in FRa-positive SKOV-3. Such effect is abrogated with ectopically expressed RFC, supporting its tumour suppressive effect in FRaexpressed cells. This in vitro finding further explains the in vivo finding that in patients with high FRa expressing ovarian cancers, the overall and disease-free survival was significantly longer in those with concomitant high RFC expression.
It has been suggested that vitamin supplements, including folate, is beneficial to health. Folate is usually taken as folic acid, its synthetic form, which is fortified in many food products. Supplementation is often believed to be of value to those who suffer from long-term illnesses. Nevertheless, the beneficial effect of folate supplement among cancer patients is controversial [12, 13, 14] . Earlier studies have shown that folate plays a dual role in colorectal, breast and prostate cancers [12, 13, 14] . Our results also indicated that folate may potentially enhance the progression and growth of ovarian cancer cells, in particular, those with high FRa and low RFC expressions. Although folate may prevent cancer initiation, once the neoplasia is established, it appears to enhance cancer progression. Should folate supplements, generally considered by the public as a healthy option, therefore be taken more cautiously? Additional studies to further explore the benefits or harmful effects of folate supplement in cancer patients are necessary.
In conclusion, we demonstrated that folate and FRa contribute to the progression and growth of ovarian cancer cells through the regulation of cell proliferation, migration and invasion. In contrast, RFC can serve as a balancing partner of FRa and seems to exert a protective role in ovarian cancer patients, conferring longer survival among patients with cancers that showed a high FRa expression status. We also demonstrated a mechanistic link between folate, FRa, RFC and E-cadherin. The potential of FRa and RFC as alternative molecular therapeutic target or prognostic marker in ovarian cancers should be further explored, respectively.
